Product Images Tadalafil
View Photos of Packaging, Labels & Appearance
- Label - 71610 0909 36
- Aphena - Aphena
- f35596a7-figure-01 - f35596a7 figure 01
- f35596a7-figure-02 - f35596a7 figure 02
- f35596a7-figure-03 - f35596a7 figure 03
- f35596a7-figure-04 - f35596a7 figure 04
- f35596a7-figure-05 - f35596a7 figure 05
- f35596a7-figure-06 - f35596a7 figure 06
- f35596a7-figure-07 - f35596a7 figure 07
- f35596a7-figure-08 - f35596a7 figure 08
- f35596a7-figure-09 - f35596a7 figure 09
Product Label Images
The following 11 images provide visual information about the product associated with Tadalafil NDC 71610-909 by Aphena Pharma Solutions - Tennessee, Llc, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Label - 71610 0909 36
Aphena - Aphena
f35596a7-figure-01 - f35596a7 figure 01
f35596a7-figure-02 - f35596a7 figure 02
This is a description of blood pressure measurements taken in standing and supine positions. It includes readings for both diastolic and systolic blood pressure. Additionally, there are time markers provided, indicating a monitoring or tracking of blood pressure changes over time.*
f35596a7-figure-03 - f35596a7 figure 03
This text provides information on a medication regimen involving Tadalafil 20 mg and doxazosin 8 mg for managing systolic blood pressure. The data seems to illustrate the effect of the medication on blood pressure levels.*
f35596a7-figure-04 - f35596a7 figure 04
This text provides information related to the impact of different medication doses on systolic blood pressure at various time points. The study mentions the administration of 20 mg tadalafil and 8 mg doxazosin at 08:00, as well as placebo and 8 mg doxazosin at the same time. Additionally, it discusses the administration of 20 mg tadalafil at 20:00 and 8 mg doxazosin at 08:00, along with placebo and 8 mg doxazosin at 08:00. The data suggests a comparison of systolic blood pressure under these different conditions over time.*
f35596a7-figure-05 - f35596a7 figure 05
f35596a7-figure-06 - f35596a7 figure 06
This information appears to be related to a study or clinical trial comparing the effectiveness of Tadalafil tablets (5 mg) versus a placebo in treating a certain condition. The data includes the change from baseline in the IPSS Total Score over a duration of treatment of 12 weeks. The results suggest a statistically significant difference (*p<0.001) between the two treatment groups.*
f35596a7-figure-07 - f35596a7 figure 07
This is a table showing the effectiveness of Tadalafil tablets 5 mg compared to a placebo over a duration of treatment in weeks. The results suggest a statistically significant difference between the two groups.*
f35596a7-figure-08 - f35596a7 figure 08
LS Mean Change from Baseline for TadalafilFinasteride and PlaceboFinasteride. The text mentions "Least Squares Treatment Difference" which may be referring to a statistical analysis for comparing the two treatments. The data seems to be related to comparing changes over time for these treatments in a study or experiment.*
f35596a7-figure-09 - f35596a7 figure 09
This text appears to be presenting data related to a study involving Tadalafil tablets at a 5mg dosage compared to a placebo. The information likely includes statistical significance indicated by "p<0.01" and a graph showing the duration of treatment in weeks.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.
